StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO - Free Report) in a report released on Friday morning. The firm issued a strong-buy rating on the medical research company's stock.
Global Cord Blood Price Performance
NYSE:CO remained flat at $1.25 during mid-day trading on Friday. 122 shares of the company were exchanged, compared to its average volume of 216,519. Global Cord Blood has a 1-year low of $2.03 and a 1-year high of $5.50. The business's 50 day moving average is $1.53 and its two-hundred day moving average is $1.40. The stock has a market capitalization of $151.94 million, a price-to-earnings ratio of 1.95 and a beta of 0.16.
About Global Cord Blood
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Articles
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
